Tropical Journal of Pharmaceutical Research

Original Research Article | OPEN ACCESS

Effect of oteracil in combination with gimeracil on long-term survival and postoperative complications in elderly patients undergoing radical surgery for biliary tract cancer

Xiaona Zhang, Tingting Zhang, Wenliang Wu, Peng Tang

Department of Surgical Oncology, Changle People’s Hospital, Weifang 262400, Shandong Province, China;

For correspondence:- Peng Tang Email: zzpfvr@163.com

Accepted: 30 May 2022 Published: 30 June 2022

Citation: Zhang X, Zhang T, Wu W, Tang P. Effect of oteracil in combination with gimeracil on long-term survival and postoperative complications in elderly patients undergoing radical surgery for biliary tract cancer. Trop J Pharm Res 2022; 21(6):1335-1340 doi: 10.4314/tjpr.v21i6.29

© 2022 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Purpose: To investigate the effect of oteracil (Oxo) in combination with gimeracil (CDHP) on long-term survival and postoperative complications in elderly patients undergoing radical surgery for biliary tract cancer (BTC).

Methods: Clinical data for 70 patients who underwent radical surgery for BTC in the Oncology Department of the Changle People’s Hospital, Weifang, China from April 2017 to April 2018 were collected. The patients were equally assigned to group A and group B, based on odd or even hospitalization number. After surgery, patients in group A received the combination of Oxo and CDHP, while group B patients received gemcitabine only. Long-term survival and incidence of adverse reactions were compared.

Results: Compared with group B, group A had higher total treatment effectiveness (p < 0.05), lower clinical indices (p < 0.05), lower BPI score (p < 0.001) and higher 3-year overall survival (p < 0.05).

Conclusion: Combined use of oteracil and gimeracil significantly prolongs the survival time and reduce cancer pain in BTC patients, with minimal toxic and side effects. However, further clinical trials are required prior to application in clinical practice.

Keywords: Oteracil, Gimeracil, Radical surgery, Biliary tract cancer, Long-term survival, Postoperative complications